Christina Lacchetti

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/718037/publications.pdf

Version: 2024-02-01

257357 477173 9,144 30 24 29 citations g-index h-index papers 30 30 30 11982 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2018, 36, 1714-1768.	0.8	2,691
2	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2014, 32, 1941-1967.	0.8	976
3	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2017, 35, 893-911.	0.8	860
4	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of Clinical Oncology, 2021, 39, 4073-4126.	0.8	580
5	Screening, Assessment, and Management of Fatigue in Adult Survivors of Cancer: An American Society of Clinical Oncology Clinical Practice Guideline Adaptation. Journal of Clinical Oncology, 2014, 32, 1840-1850.	0.8	486
6	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. Journal of Clinical Oncology, 2020, 38, 3325-3348.	0.8	457
7	Management of Chronic Pain in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2016, 34, 3325-3345.	0.8	413
8	Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Clinical Oncology, 2019, 37, 423-438.	0.8	384
9	Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. Journal of Oncology Practice, 2019, 15, 106-107.	2.5	281
10	Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. Journal of Clinical Oncology, 2016, 34, 1689-1701.	0.8	243
11	Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2018, 14, 247-249.	2.5	219
12	Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation of Cancer Care Ontario Guideline. Journal of Clinical Oncology, 2018, 36, 492-511.	0.8	208
13	Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1222-1245.	0.8	202
14	PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 3468-3493.	0.8	175
15	Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement of the College of American Pathologists Guideline. Journal of Clinical Oncology, 2018, 36, 3152-3161.	0.8	153
16	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline. Journal of Clinical Oncology, 2019, 37, 2916-2946.	0.8	127
17	Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline. Journal of Clinical Oncology, 2021, 39, 3978-3992.	0.8	121
18	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Cancer Society Guideline. Journal of Clinical Oncology, 2017, 35, 1606-1621.	0.8	112

#	Article	IF	CITATIONS
19	Prostate Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. Journal of Clinical Oncology, 2015, 33, 1078-1085.	0.8	108
20	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2017, 13, 270-275.	2.5	85
21	Validating Whole Slide Imaging Systems for Diagnostic Purposes in Pathology. Archives of Pathology and Laboratory Medicine, 2022, 146, 440-450.	1.2	73
22	Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline Summary. Journal of Oncology Practice, 2014, 10, e421-e424.	2.5	60
23	Quantitative Image Analysis of Human Epidermal Growth Factor Receptor 2 Immunohistochemistry for Breast Cancer: Guideline From the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2019, 143, 1180-1195.	1.2	49
24	Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline Summary. JCO Oncology Practice, 2020, 16, e835-e838.	1.4	31
25	Head and Neck Cancer Survivorship Care Guideline: American Society of Clinical Oncology Clinical Practice Guideline Endorsement Summary. Journal of Oncology Practice, 2018, 14, 167-171.	2.5	14
26	Human Papillomavirus Testing in Head and Neck Carcinomas: ASCO Clinical Practice Guideline Endorsement Summary of the CAP Guideline. Journal of Oncology Practice, 2018, 14, 613-617.	2.5	12
27	Management of the Top 10 Most Common Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy. JCO Oncology Practice, 2022, 18, 431-444.	1.4	11
28	Interventions to Address Sexual Problems in People With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Adaptation Summary. Journal of Oncology Practice, 2018, 14, 173-179.	2.5	8
29	Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline Summary. Journal of Oncology Practice, 2019, 15, 665-669.	2.5	5
30	Reply to E. Gonzalez-Rodriguez et al. Journal of Clinical Oncology, 2020, 38, 1642-1643.	0.8	0